PT - JOURNAL ARTICLE AU - Shankar Prinja AU - Pankaj Bahuguna AU - Yashika Chugh AU - Anna Vassall AU - Arvind Pandey AU - Sumit Aggarwal AU - Narendra Kumar Arora TI - A Model Based Analysis for COVID-19 Pandemic in India: Implications for Health Systems and Policy for Low- and Middle-Income Countries AID - 10.1101/2020.06.11.20128231 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.11.20128231 4099 - http://medrxiv.org/content/early/2020/06/12/2020.06.11.20128231.short 4100 - http://medrxiv.org/content/early/2020/06/12/2020.06.11.20128231.full AB - Background Our analysis aims to model COVID-19 pandemic in India, potential impact of various measures, along with assessment of health system preparedness and cost to manage the epidemic.Methods We developed a susceptible-exposed-infectious-recovered (SEIR) mathematical model to predict the health outcomes under an unmitigated scenario which comprises of air travel restrictions alone, and the current scenario consisting of air travel restrictions along with 8-week lockdown. In addition, we also evaluate the effectiveness of 8-week lockdown along with intensified public health measures at varying level of effectiveness. We assessed the impact of these interventions on COVID-19 related health outcomes in comparison to the unmitigated scenario. Next, we ascertain the need for augmenting infrastructure and the costs of COVID-19 management in India.Findings In the event of a lockdown for 8 weeks, the peak of the epidemic shifts by 34-76 days, and the number of cases at the end of 8-week lockdown reduces by 69% to 97% with varying effectiveness of lockdown. However, the cumulative long-term cases remain the same. Intensification of public health surveillance measures with 60% effectiveness is estimated to reduce the cases at peak and cumulative number of infections by 70% and 26.6% respectively. The requirement of ICU beds and ventilators would reduce by 83% with intensified public health measures. The cost of managing COVID-19 in India is nearly 4.5% of the gross domestic product (GDP) in the absence of any intervention which increases to 6.2% with intensified public health measures for COVID-19 response.Conclusion Lockdown measures delay the onset of peak, and give much needed time to health system to prepare. Strengthening the public health system response in terms of testing, isolation treatment of cases, and contact tracing needs would lead to significant gains in terms of case load, and meeting health system needs.What is already known?A few studies have been carried out in Indian context to model the epidemic. These models explored the impact of lockdowns and social distancing measures focusing more on the course of the epidemic but none of these evaluated the impact on health system’s response needed as well as the economic impact of COVID-19 management in India. The findings from these studies are limited in a sense that either these studies evaluated the hypothetical scenarios of strategies implemented or focusing to smaller geographical regions in India.What are the new findings?Evidence pertaining to health economic impact of COVID-19 management, in context to Low- and Middle-Income countries, is very limited. To address this, we used the susceptible-exposed-infectious-recovered (SEIR) model to assess:the health system preparedness challenge in terms of hospital beds for isolation, intensive care and ventilators which would be required to manage the epidemic and the economic implications of managing the COVID-19 pandemic in India.the incremental cost of intensified public health measures per infection and per death averted.What do the new finding imply?In India, measures such as lockdowns would certainly delays the onset of peak of COVID-19 epidemic. This would help delay the surge of cases, which would buy time for the health system to prepare. Strengthening the health system response in terms of enhanced testing, isolation of cases, treatment and contact tracing, as is being done currently, would have to be the mainstay to reduce the impact of the pandemic in terms of reduction in infected population and COID-19 deaths in India until vaccine becomes available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe present study was funded by Indian Council of Medical Research, IndiaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study has been conceived as part of the National COVID-19: Taskforce Operations Research (NTF OR) Group. Technical approval of the study protocol has been given by the NTF-OR. The present study has been approved by the Institute Ethics Committee of Post Graduate Institute of Medical Education and Research, Chandigarh, India. It is also approved by the Institute Collaborative Research Committee of the PGIMER Chandigarh.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the neccessary data is given in the main article file or attached as supplementary files.